Velexbru (tirabrutinib hydrochloride) vs Lunsumio (mosunetuzumab-axgb)
Velexbru (tirabrutinib hydrochloride) vs Lunsumio (mosunetuzumab-axgb)
Velexbru (tirabrutinib hydrochloride) is a small molecule inhibitor specifically targeting Bruton's tyrosine kinase (BTK), primarily used in the treatment of various B-cell malignancies, such as mantle cell lymphoma. Lunsumio (mosunetuzumab-axgb), on the other hand, is a bispecific T-cell engager antibody that redirects T-cells to engage and eliminate B-cells, which is used for the treatment of relapsed or refractory follicular lymphoma. When deciding between these medications, a patient should consider factors such as the specific type of lymphoma they have, their previous treatments and responses, potential side effects, and the mechanism of action of each drug, in consultation with their healthcare provider.
Difference between Velexbru and Lunsumio
| Metric | Velexbru (tirabrutinib hydrochloride) | Lunsumio (mosunetuzumab-axgb) |
|---|---|---|
| Generic name | Tirabrutinib hydrochloride | Mosunetuzumab-axgb |
| Indications | Approved for the treatment of various B-cell malignancies, including mantle cell lymphoma and chronic lymphocytic leukemia. | Approved for the treatment of relapsed or refractory follicular lymphoma. |
| Mechanism of action | Bruton's tyrosine kinase (BTK) inhibitor, which blocks B-cell receptor signaling involved in the growth and survival of malignant B cells. | Bispecific T-cell engager that binds to both CD20 on B cells and CD3 on T cells, leading to the activation and redirection of T cells to engage and eliminate B cells. |
| Brand names | Velexbru | Lunsumio |
| Administrative route | Oral | Intravenous infusion |
| Side effects | May include diarrhea, neutropenia, rash, anemia, and thrombocytopenia. | May include cytokine release syndrome, infusion-related reactions, fatigue, and hepatotoxicity. |
| Contraindications | Known hypersensitivity to tirabrutinib or any component of the formulation. | Known hypersensitivity to mosunetuzumab-axgb or any component of the formulation. |
| Drug class | Bruton's tyrosine kinase (BTK) inhibitor | Bispecific monoclonal antibody |
| Manufacturer | Asahi Kasei Pharma | Genentech, a member of the Roche Group |
Efficacy
Velexbru (Tirabrutinib Hydrochloride) Efficacy in Lymphoma
Velexbru, known by its generic name tirabrutinib hydrochloride, is a Bruton's tyrosine kinase (BTK) inhibitor that has shown promising results in the treatment of certain types of lymphoma. Specifically, tirabrutinib has demonstrated efficacy in treating relapsed or refractory mantle cell lymphoma (MCL), which is a subtype of non-Hodgkin lymphoma. Studies have indicated that tirabrutinib can lead to a high overall response rate in patients with this condition, offering a valuable option for those who have not responded to or have relapsed after other treatments.
In clinical trials, Velexbru has shown a favorable safety profile and a significant antitumor activity in patients with B-cell malignancies. The efficacy of tirabrutinib in B-cell lymphoma is attributed to its ability to selectively inhibit BTK, which is an essential component in the B-cell receptor signaling pathway. This inhibition disrupts the survival and proliferation of malignant B cells, leading to their apoptosis and potentially resulting in tumor regression.
Lunsumio (Mosunetuzumab-axgb) Efficacy in Lymphoma
Lunsumio, with the generic name mosunetuzumab-axgb, is a bispecific T-cell engager antibody that has been developed for the treatment of lymphoma. It is designed to target both CD20 on B cells and CD3 on T cells, thereby bringing these two cell types into close proximity and inducing T-cell mediated cytotoxicity against the B cells. This mechanism of action has shown considerable efficacy in non-Hodgkin lymphoma, particularly in follicular lymphoma, where Lunsumio has been used in patients who have received at least two prior systemic therapies.
Clinical trials have demonstrated that Lunsumio can induce complete remission in a significant proportion of patients with relapsed or refractory follicular lymphoma. The therapy has been particularly beneficial for individuals who have limited treatment options due to the refractory nature of their disease. The efficacy of Lunsumio in inducing remission and its manageable safety profile suggest that it could become an important therapeutic option for patients with difficult-to-treat B-cell lymphomas.
Regulatory Agency Approvals
Velexbru
-
Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Lunsumio
-
European Medical Agency (EMA), European Union
-
Food and Drug Administration (FDA), USA
Access Velexbru or Lunsumio today
If Velexbru or Lunsumio are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us